BIOFABRI
Biofabri was founded in 2008 with a vision to research and develop human vaccines. As a biopharmaceutical company focused on human health, it possesses strong technical and development capabilities, with a proven track record. Part of the Zendal group, Biofabri specializes in the research, development, manufacturing, and marketing of vaccines and biotechnological medicinal products for human health. The company is committed to continuous innovation in biotechnology, investing heavily in R&D, and collaborates with prestigious universities and research centers. Its most advanced project is the vaccine against tuberculosis, MTBVAC, currently in clinical trials.
Industries
Nr. of Employees
medium (51-250)
BIOFABRI
A Relva, Torneiros s/n 36410 O Porriño, Pontevedra, Spain
Patents
Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
US-11826411-B2
View Details
Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
US-11826411-B2
View DetailsProducts
MTBVAC (live-attenuated M. tuberculosis vaccine candidate)
A genetically attenuated live vaccine derived from Mycobacterium tuberculosis designed to retain pathogen antigen repertoire while being attenuated to avoid disease; evaluated in preclinical models and multiple clinical trials for safety, immunogenicity and efficacy.
IMMUNO BCG (immunotherapy for superficial bladder carcinoma)
An immunotherapy approach intended to reduce recurrence of superficial bladder carcinoma through immune stimulation.
Pharmaceutical probiotic formulations (development and manufacturing)
Probiotic product lines under development for pediatric and women's health indications; full development from strain selection to finished product manufactured under pharmaceutical standards.
MTBVAC (live-attenuated M. tuberculosis vaccine candidate)
A genetically attenuated live vaccine derived from Mycobacterium tuberculosis designed to retain pathogen antigen repertoire while being attenuated to avoid disease; evaluated in preclinical models and multiple clinical trials for safety, immunogenicity and efficacy.
IMMUNO BCG (immunotherapy for superficial bladder carcinoma)
An immunotherapy approach intended to reduce recurrence of superficial bladder carcinoma through immune stimulation.
Pharmaceutical probiotic formulations (development and manufacturing)
Probiotic product lines under development for pediatric and women's health indications; full development from strain selection to finished product manufactured under pharmaceutical standards.
Services
End-to-end development and manufacturing services for vaccine and biologic products from development through clinical phases I–III and commercial-scale production. Includes access to multiple biotechnology manufacturing plants and EU GMP-compliant facilities.
Design and operational support for safety, dose-defining and immunogenicity clinical trials, including coordination with clinical research centers in endemic regions for site execution.
End-to-end development and manufacturing of probiotic products under pharmaceutical standards, including segregated production areas and environmental control systems to ensure product stability and prevent cross-contamination.
Management and participation in multi-institutional research consortia and administration of externally funded projects (EU, national agencies) for vaccine and pandemic-response R&D.
End-to-end development and manufacturing services for vaccine and biologic products from development through clinical phases I–III and commercial-scale production. Includes access to multiple biotechnology manufacturing plants and EU GMP-compliant facilities.
Design and operational support for safety, dose-defining and immunogenicity clinical trials, including coordination with clinical research centers in endemic regions for site execution.
End-to-end development and manufacturing of probiotic products under pharmaceutical standards, including segregated production areas and environmental control systems to ensure product stability and prevent cross-contamination.
Management and participation in multi-institutional research consortia and administration of externally funded projects (EU, national agencies) for vaccine and pandemic-response R&D.
Expertise Areas
- Vaccine discovery and development
- Live-attenuated vaccine engineering
- Clinical trial management and operations
- Biologics contract development and manufacturing (CDMO)
Key Technologies
- Genetically engineered live-attenuated vaccines
- Recombinant subunit (protein) vaccines
- RNA and DNA vaccine platforms
- Antigen design and epitope retention strategies
News & Updates
Two new clinical trials will begin in January 2018 in 99 newborns and 120 adults in South Africa, supported by 12 million euros from the EU and US, to evaluate the safety and immunogenicity of the TB vaccine MTBVAC.
A detailed study on the development and preclinical evaluation of MTBVAC, a live-attenuated vaccine for tuberculosis.
MTBVAC is the only live-attenuated M. tuberculosis vaccine evaluated in clinical trials that has demonstrated safety, efficacy, and immunogenicity, making it one of the most promising TB vaccines worldwide.
Two new clinical trials will begin in January 2018 in 99 newborns and 120 adults in South Africa, supported by 12 million euros from the EU and US, to evaluate the safety and immunogenicity of the TB vaccine MTBVAC.
A detailed study on the development and preclinical evaluation of MTBVAC, a live-attenuated vaccine for tuberculosis.
MTBVAC is the only live-attenuated M. tuberculosis vaccine evaluated in clinical trials that has demonstrated safety, efficacy, and immunogenicity, making it one of the most promising TB vaccines worldwide.